Denosumab in men receiving androgen-deprivation therapy for prostate cancer. [electronic resource]
Producer: 20090827Description: 745-55 p. digitalISSN:- 1533-4406
- Aged
- Aged, 80 and over
- Androgen Antagonists -- adverse effects
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Bone Density -- drug effects
- Bone Density Conservation Agents -- adverse effects
- Bone Remodeling -- drug effects
- Denosumab
- Double-Blind Method
- Fractures, Bone -- epidemiology
- Gonadotropin-Releasing Hormone -- agonists
- Humans
- Incidence
- Injections, Subcutaneous
- Lumbar Vertebrae -- drug effects
- Male
- Middle Aged
- Orchiectomy
- Osteoporosis -- chemically induced
- Prostatic Neoplasms -- drug therapy
- RANK Ligand -- adverse effects
- Spinal Fractures -- epidemiology
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.